Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Sep 16;116(11):1839-48.
doi: 10.1182/blood-2010-04-278317. Epub 2010 Jun 10.

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

Vikas Gupta  1 , Martin S Tallman, Wensheng He, Brent R Logan, Edward Copelan, Robert Peter Gale, Hanna J Khoury, Thomas Klumpp, John Koreth, Hillard M Lazarus, David I Marks, Rodrigo Martino, David A Rizzieri, Jacob M Rowe, Mitchell Sabloff, Edmund K Waller, John F DiPersio, Donald W Bunjes, Daniel J Weisdorf
Affiliations
Comparative Study

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

Vikas Gupta et al. Blood. .

Abstract

We compared the outcomes of unrelated donor (URD, n = 358) with human leukocyte antigen (HLA)-matched sibling donor (MSD, n = 226) transplantations in patients with acute myeloid leukemia (AML) in first complete remission (CR1) having unfavorable cytogenetics at diagnosis. Unfavorable cytogenetic abnormalities were: complex (≥ 3 abnormalities), 32%; and noncomplex involving chromosome 7, 25%; chromosome 5, 9%; 11q or MLL rearrangements, 18%; t(6;9), 5%; and other noncomplex, 10%. URDs were HLA-well-matched (n = 254; 71%) or partially-matched (n = 104; 29%). Three-year leukemia-free survival (LFS) for MSD was 42% (95% confidence interval [CI], 35%-48%) compared with 34% (95% CI, 28%-41%) for HLA-well-matched URD and 29% (95% CI, 20%-39%) for partially-matched URD (P = .08). In multivariate analysis, HLA-well-matched URD and MSD yielded similar LFS (relative risk [RR] = 1.1, 95% CI, 0.86-1.40, P = .44) and overall survival (OS; RR = 1.06, 95% CI, 0.83-1.37, P = .63). LFS and OS were significantly inferior for HLA-partially-matched URD recipients, those with prior myelodysplastic syndrome, and those older than 50 years. All cytogenetic cohorts had similar outcomes. Patients with chronic graft-versus-host disease had a significantly lower risk of relapse (RR = 0.68, 95% CI, 0.47-0.99, P = .05). Hematopoietic cell transplantation (HCT) using HLA-well-matched URD and MSD resulted in similar LFS and OS in AML patients in CR1 with unfavorable cytogenetics. Outcomes of HCT from HLA-partially- matched URD were inferior.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparisons of MSD, HLA-well-matched URD, and partially-matched URD transplantation in AML patients in CR1 with unfavorable cytogenetics. (A) Cumulative incidence of TRM. (B) Cumulative incidence of relapse. (C) Adjusted probability of LFS. (D) Adjusted probability of OS.
Figure 2
Figure 2
Impact of various unfavorable cytogenetic subsets on relapse.
See this image and copyright information in PMC

Comment in

  • Transplantation in AML CR1.
    Savani BN. Savani BN. Blood. 2010 Sep 16;116(11):1822-3. doi: 10.1182/blood-2010-06-291500. Blood. 2010. PMID: 20847206 No abstract available.

References

    1. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103(8):1652–1658. - PubMed
    1. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–2361. - PMC - PubMed
    1. Krauter J, Heil G, Hoelzer D, et al. Treatment of patients up to 60 years with high risk AML: final results of the AML SHG-Hannover 01/99 Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2006;108(11) Abstract 433.
    1. Basara N, Schulze A, Wedding U, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia. 2009;23(4):635–640. - PubMed
    1. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99(6):1971–1977. - PubMed

Publication types

MeSH terms